Aβ42 and tau proteins in CSF are validated biomarkers of AD and are integral to the ATN framework, which serves not only diagnostic and classification purposes but also has significant prognostic implications, since individuals with MCI who are positive for all markers show the highest likelihood of progression to dementia [115]. Here, MAPT is linked to Alzheimer disease.